Publications by authors named "L Ampollini"
Article Synopsis
- The study investigates if tracking changes in CT radiomic features and systemic inflammatory indices over time is better at predicting survival for advanced non-small cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors compared to a one-time assessment.
- Researchers analyzed data from 90 NSCLC patients, calculating variations in radiomic features from initial treatment to first disease assessment, and found that these changes (Δ-RAD) were more predictive of overall survival (OS) than baseline measures alone.
- The best predictive results came from combining Δ-RAD with longitudinal clinical and inflammatory data, achieving significant improvements in overall survival predictions and allowing better patient risk stratification.
Background: Resistance to osimertinib in advanced EGFR-mutated non-small cell lung cancer (NSCLC) constitutes a significant challenge for clinicians either in terms of molecular diagnosis and subsequent therapeutic implications.
Methods: This is a prospective single-centre study with the primary objective of characterising resistance mechanisms to osimertinib in advanced EGFR-mutated NSCLC patients treated both in first- and in second-line. Next-Generation Sequencing analysis was conducted on paired tissue biopsies and plasma samples.
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity.
Explor Target Antitumor Ther
August 2023
Aim: In renal cell carcinoma (RCC), tumor heterogeneity generated challenges to biomarker development and therapeutic management, often becoming responsible for primary and acquired drug resistance. This study aimed to assess the inter-tumoral, intra-tumoral, and intra-lesional heterogeneity of known druggable targets in metastatic RCC (mRCC).
Methods: The RIVELATOR study was a monocenter retrospective analysis of biological samples from 25 cases of primary RCC and their paired pulmonary metastases.
Article Synopsis
- Pleural mesothelioma (PM) is a serious cancer that is becoming more common in Europe, and understanding its epidemiology, treatment, and prognosis is crucial for improving patient outcomes.
- A study analyzed data from 2,766 PM patients across multiple European centers, revealing that most patients had the epithelioid subtype of PM and that many presented at advanced stages (III to IV) with poor overall survival rates averaging 17.4 months.
- Results indicated that treatment approaches, particularly multimodality treatments including surgery, notably improved survival chances, especially in patients who achieved a complete resection of the tumor.
Background: The role of salvage surgery after tyrosine kinase inhibitors in advanced oncogene-addicted non-small cell lung cancer is largely unexplored.
Patients: We aimed to describe the pathological features and surgical early-outcomes of Anaplastic Lymphome Kinase anaplastic lymphome kinase positive non-small cell lung cancer patients undergoing surgery after first-line alectinib treatment. We retrospectively collected and analyzed multicentric data of 10 patients treated with alectinib for advanced-stage anaplastic lymphome kinase positive lung adenocarcinoma who underwent anatomical surgical resection from January 2020 to Decemeber 2021.